A DLEU2/E2F1 regulatory axis promotes migration and invasion phenotypes in cervical squamous cell carcinoma Authors: Min He, Shiyi Huang, Mingjiang Wang, Tangrui Zhu, Jinhua Ding, Yitao Wang, Mingbo Liu, Hanlu Wen Published: 2026 ABSTRACT Cervical squamous cell carcinoma (CSCC), the most prevalent form of cervical cancer, is often diagnosed at advanced stages with limited treatment efficacy. Cell migration and invasion are critical steps, yet its molecular mechanisms remain poorly understood. This study investigates the role of the long non‑coding RNA DLEU2 in CSCC migration and invasion. RNA sequencing of 7 invasive CSCC and 7 normal cervical tissues revealed significant upregulation of DLEU2 in tumors, which correlated with poor prognosis in advanced‑stage patients. Functionally, DLEU2 knockdown suppressed, while its overexpression promoted, cancer cell migration and invasion in vitro. Mechanistically, we identified a DLEU2/E2F1 regulatory axis: E2F1 transcriptionally activates DLEU2, and DLEU2 in turn interacts with and may regulate E2F1 at transcription and post‑transcriptional level. Ectopic overexpression of E2F1 rescued the migratory and invasive impairments induced by DLEU2 silencing. Furthermore, DLEU2 regulated key migration and invasion‑related genes, including SNAI2 and MMP9. Together, our findings suggest an association between DLEU2 and E2F1 that may contribute to pro-migratory and pro-invasive phenotypes in CSCC, potentially offering this axis as a candidate therapeutic target.Supplementary InformationThe online version contains supplementary material available at 10.1038/s41598-026-51939-4. Introduction Cervical cancer (CC) remains a major global health burden, ranking as the fourth most common cause of cancer-related mortality among women worldwide1. Invasive cervical squamous cell carcinoma (CSCC), which constitutes 70%–80% of all CC cases, is responsible for the majority of this morbidity and mortality2. While persistent infection with high-risk human papillomavirus (HR-HPV) is the established etiological driver in nearly all cases, the progression to invasive and metastatic disease is governed by complex host molecular alterations3. Although widespread screening and HPV vaccination have improved early detection and prevention, a significant number of patients still present with advanced-stage disease3. While early-stage CSCC is often curable with surgery or radiotherapy, the therapeutic options for advanced or recurrent CSCC—primarily chemotherapy, immunotherapy, and targeted therapies—are limited in efficacy and associated with poor long-term survival4. Consequently, a deeper understanding of the molecular mechanisms that promote CSCC cell migration, invasion, and motility is imperative for developing more effective therapeutic strategies. In recent years, long non-coding RNAs (lncRNAs) have emerged as pivotal regulators in oncogenesis, critically influencing tumor growth, invasion, and metastatic dissemination5,6. Among these, the lncRNA DLEU2 has been implicated in the progression of diverse malignancies, positioning it as a potential pan-cancer biomarker and therapeutic target7. For instance, DLEU2 forms a regulatory loop with ROR1 to promote epithelial–mesenchymal transition (EMT) in breast cancer8, interacts with EZH2 to drive hepatocellular carcinoma proliferation9, and facilitates tumor cell infiltration in non-small cell lung cancer and pancreatic cancer10,11. Furthermore, in gastric cancer, DLEU2 silencing suppresses invasion and migration by inhibiting the PI3K/AKT pathway12. Notably, within the context of cervical cancer, existing evidence indicates that DLEU2 contributes to cell proliferation13. However, despite these insights, a critical knowledge gap persists. Invasion and metastasis—processes initiated by the acquisition of migratory and invasive capabilities by cancer cells—are the principal determinants of lethality in advanced CSCC14,15. While DLEU2’s role in proliferation is recognized, its precise function and underlying molecular mechanism in driving these lethal, invasive phenotypes in CSCC remain largely unexplored. Crucially, it is unknown whether DLEU2 operates through core oncogenic transcriptional networks to orchestrate pro-migratory and pro-invasive programs. To address this, we performed an integrated transcriptomic analysis using RNA sequencing (RNA-Seq) of clinical CSCC specimens and public datasets (TCGA, GEO). We aimed to rigorously define the role of DLEU2 in CSCC cell migration and invasion. Our results confirm that DLEU2 is significantly upregulated in CSCC and its high expression correlates with poor prognosis in advanced disease. Through a series of functional experiments, we demonstrate that DLEU2 is a potential contributor of cervical cancer cell migration and invasion in vitro. Most importantly, we identify and characterize a potential regulatory axis centered on the transcription factor E2F1, through which DLEU2 executes its pro-migratory and pro-invasive effects. Results Analysis of differentially expressed genes in invasive CSCC RNA sequencing of 7 invasive cervical squamous cell carcinoma (CSCC) and 7 normal cervical tissue samples revealed distinct expression profiles of lncRNAs and mRNAs (Fig. 1A). The data have been deposited in the NCBI GEO database (accession: GSE291247). To enhance reliability, we integrated publicly available CSCC datasets from TCGA and GEO. Differentially expressed genes (DEGs) were defined as those with p‑value < 0.05 and |LogFC|> 1. Our RNA‑seq data yielded 7272 DEGs (3810 upregulated, 3462 downregulated), TCGA data contained 7128 DEGs (3483 upregulated, 3645 downregulated), and GSE63514 included 3654 DEGs (2359 upregulated, 1295 downregulated) (Fig. 1B). The substantial overlap of dysregulated genes across datasets indicates widespread transcriptomic alterations in CSCC, likely contributing to tumorigenesis.Fig. 1Differential gene expression analysis in CSCC. (A) Heatmap of RNA-seq for 7 invasive CSCC samples and 7 normal cervical tissue samples. (B) Volcano plots of differential gene expression analysis in CSCC tissue samples, TCGA, and GEO datasets. (C) Venn diagram and heatmap of differentially expressed genes (DEGs) in the three datasets. Differential gene expression analysis in CSCC. (A) Heatmap of RNA-seq for 7 invasive CSCC samples and 7 normal cervical tissue samples. (B) Volcano plots of differential gene expression analysis in CSCC tissue samples, TCGA, and GEO datasets. (C) Venn diagram and heatmap of differentially expressed genes (DEGs) in the three datasets. Venn analysis of the three DEG sets identified 439 consistently altered genes (Fig. 1C), including 6 lncRNAs (AATBC, DLEU2, LINC00467, LINC01305, LINC00925, NRAV) and 46 transcription factors (TFs), suggesting that lncRNA–TF–mRNA networks may participate in CSCC pathogenesis. Functional enrichment analysis (GO, KEGG, Reactome)16 of these common DEGs showed significant association with cell‑cycle processes such as nuclear division, chromosome segregation, and G1/S transition (Supplementary Fig. 1A–D), underscoring dysregulated cell‑cycle gene expression as a key feature of CSCC. Potential role of the lncRNA DLEU2 in the development of CSCC To prioritize lncRNAs for functional study, we integrated differential expression analysis with target gene prediction. Among the six consistently upregulated lncRNAs, DLEU2 exhibited the highest number of potential target genes (618) according to the ENCORI database (Fig. 2A), suggesting a broad regulatory capacity. Both RNA‑seq and microarray data confirmed DLEU2 upregulation in tumor tissues (Fig. 2B). Survival analysis indicated using the TCGA‑CSCC cohort indicated that high DLEU2 expression correlated with poor prognosis in advanced‑stage cervical cancer patients (n = 65 advanced-stage; n = 230 early-stage; p < 0.05), but not in early‑stage cases (Fig. 2C). These findings led us to focus on DLEU2 for subsequent mechanistic studies.Fig. 2The potential role of DLEU2 in the development of CSCC. (A) Bar plot of lncRNA target gene number. The ENCORI database was used to query all the possible target genes for lncRNA and to visualize the number of genes. (B) Box plot of DLEU2 expression in RNA-seq and chip datasets. (C) Survival analysis. Kaplan–Meier curves for DLEU2 expression in CC patients with early and late-stage disease. (D,E) Functional analysis. Gene ontology analysis and network construction of the DEGs using R and Metascape. The potential role of DLEU2 in the development of CSCC. (A) Bar plot of lncRNA target gene number. The ENCORI database was used to query all the possible target genes for lncRNA and to visualize the number of genes. (B) Box plot of DLEU2 expression in RNA-seq and chip datasets. (C) Survival analysis. Kaplan–Meier curves for DLEU2 expression in CC patients with early and late-stage disease. (D,E) Functional analysis. Gene ontology analysis and network construction of the DEGs using R and Metascape. TCGA samples were stratified into DLEU2‑high and ‑low groups based on mean expression. Differential expression analysis followed by GO enrichment (Metascape) revealed that DEGs were enriched in processes related to cell differentiation, motility, migration, and adhesion—key features of invasion and motility (Fig. 2D,E). While our prior work showed that DLEU2 promotes proliferation via cell‑cycle and NOTCH signaling13, its role in migration and invasion remained unclear. Together, these data suggest that DLEU2 contributes to CSCC progression not only through proliferation pathways but also by potentially regulating cellular motility and invasive behavior. DLEU2 promotes CC cell migration and invasion in vitro DLEU2 was knocked down or overexpressed in HeLa and SiHa cells, with efficiency confirmed by qPCR (Supplementary Fig. 2A,B). Transwell assays revealed that DLEU2 depletion significantly reduced migration and invasion in both cell lines (Fig. 3A). Consistently, wound‑healing assays showed diminished migration upon DLEU2 silencing (Supplementary Fig. 3A,B). Further quantification of motility using real‑time cell tracking (JULI Stage Recorder) demonstrated that DLEU2 knockdown decreased total migration distance (Fig. 3B), while its overexpression enhanced cell movement (Supplementary Fig. 4A,B). Importantly, all these functional assays (Transwell, wound‑healing, and cell motility assays) were completed within 24 h—a timeframe during which we cannot completely exclude potential confounding effects from alterations in proliferation, viability, apoptosis, or cell-cycle progression. Accordingly, while our findings suggest that DLEU2 regulates migratory and invasive capacity beyond its effects on proliferation, we acknowledge that an effect independent of proliferation has not been directly demonstrated. Collectively, these results suggest that DLEU2 expression positively regulates migration, invasion, and motility in cervical cancer cells in vitro.Fig. 3DLEU2 silencing suppresses CC cell migration, invasion and motility. After transfecting with siRNAs, CC cells were performed on transwell assay (A) and cell motility assay (B). (A) Transwell migration and invasion assay. The migratory and invasive abilities of Hela and SiHa cells transfected with si233 and si608 were significantly reduced compared to the cells transfected with siNC. (B) Cell motility assay. Transfected HeLa and SiHa cells were seeded into 6-well plates and their motility continuously monitored with a JULI Stage Real-time Cell History Recorder. The migration distance and velocity of HeLa and SiHa cells transfected with si233 and si608 were significantly decreased. Error bars represent the SD of the mean. **p < 0.01, ***p < 0.001. Scale bar: 500 µm. DLEU2 silencing suppresses CC cell migration, invasion and motility. After transfecting with siRNAs, CC cells were performed on transwell assay (A) and cell motility assay (B). (A) Transwell migration and invasion assay. The migratory and invasive abilities of Hela and SiHa cells transfected with si233 and si608 were significantly reduced compared to the cells transfected with siNC. (B) Cell motility assay. Transfected HeLa and SiHa cells were seeded into 6-well plates and their motility continuously monitored with a JULI Stage Real-time Cell History Recorder. The migration distance and velocity of HeLa and SiHa cells transfected with si233 and si608 were significantly decreased. Error bars represent the SD of the mean. **p < 0.01, ***p < 0.001. Scale bar: 500 µm. DLEU2 promotes CC cell migration and invasion through association with E2F1 Given the established regulatory interplay among lncRNAs, transcription factors (TFs), and mRNAs, we hypothesized that DLEU2 might operate within such a network. Intersection of the 618 predicted DLEU2 target genes with the 46 differentially expressed TFs from our CSCC RNA‑seq data identified only four overlapping TFs (Fig. 4A). Among these, E2F1 was selected for further study due to the well‑characterized role of the E2F family in core oncogenic processes, including proliferation, differentiation, and invasion. E2F family members have been linked to aggressive clinicopathological features and poor survival in cervical cancer17. In line with this, our RNA‑seq analysis of invasive CSCC tissues confirmed significant upregulation of E2F1 (logFC = 2.76, P < 0.01). Additionally, the expression of DLEU2 and E2F1 was analyzed across multiple datasets. In cervical cancer tissues, a significant positive correlation between DLEU2 and E2F1 was observed in the GSE63514 cohort (Fig. 4B) as well as in our CSCC RNA-seq clinical samples (Supplementary Fig. S5D). In cell line models, DLEU2 and E2F1 expression levels were profiled using the CCLE database (Supplementary Fig. S5A–B), and their correlation was further confirmed in CCLE CSCC cell lines (Supplementary Fig. S5C). Moreover, high co‑expression of DLEU2 and E2F1 in the TCGA cohort was significantly associated with unfavorable prognosis (Fig. 4C).Fig. 4Regulatory association between DLEU2 and E2F1. (A) Venn diagram of the differentially expressed TFs and DLEU2 target genes. Only 4 TFs were common to both sets. (B) Correlation between DLEU2 and E2F1 expression was assessed using GSE63514 dataset(cervical cancer tissue data). (C) Survival analysis. Kaplan–Meier curves for co-expression of DLEU2 and E2F1. (D–F) Western blot analysis of E2F1 protein expression in CC cells. (D) E2F1 protein expression in HeLa and SiHa cells with DLEU2 knockdown. (E) E2F1 protein expression in HeLa cells with DLEU2 overexpression. (F) E2F1 protein expression in HeLa cells with E2F1 overexpression. (G) RNA expression of E2F1 and DLEU2 in CC cells with E2F1 overexpression. qRT-PCR was performed to examine the E2F1 and DLEU2 expression after HeLa cells transfecting with pcDNA3.1-E2F1. (H) Chiq-seq data for E2F1 in HeLa cells downloaded from ENCODE. (I) E2F1 protein expression in HeLa cells after RNA-pulldown. Biotin-labeled probes of sense and antisense strands of DLEU2 transcribed in vitro were incubated with protein lysates of HeLa cells for RNA-pulldown. E2F1 protein was then detected by Western blotting. (J,K) Dual-Luciferase Reporter Assay. Hela cells were transiently transfected with the indicated plasmids, and the luciferase activities measured after transfection for 48 h. Error bars represent the SD of the mean. **p < 0.01, ***p < 0.001. Regulatory association between DLEU2 and E2F1. (A) Venn diagram of the differentially expressed TFs and DLEU2 target genes. Only 4 TFs were common to both sets. (B) Correlation between DLEU2 and E2F1 expression was assessed using GSE63514 dataset(cervical cancer tissue data). (C) Survival analysis. Kaplan–Meier curves for co-expression of DLEU2 and E2F1. (D–F) Western blot analysis of E2F1 protein expression in CC cells. (D) E2F1 protein expression in HeLa and SiHa cells with DLEU2 knockdown. (E) E2F1 protein expression in HeLa cells with DLEU2 overexpression. (F) E2F1 protein expression in HeLa cells with E2F1 overexpression. (G) RNA expression of E2F1 and DLEU2 in CC cells with E2F1 overexpression. qRT-PCR was performed to examine the E2F1 and DLEU2 expression after HeLa cells transfecting with pcDNA3.1-E2F1. (H) Chiq-seq data for E2F1 in HeLa cells downloaded from ENCODE. (I) E2F1 protein expression in HeLa cells after RNA-pulldown. Biotin-labeled probes of sense and antisense strands of DLEU2 transcribed in vitro were incubated with protein lysates of HeLa cells for RNA-pulldown. E2F1 protein was then detected by Western blotting. (J,K) Dual-Luciferase Reporter Assay. Hela cells were transiently transfected with the indicated plasmids, and the luciferase activities measured after transfection for 48 h. Error bars represent the SD of the mean. **p < 0.01, ***p < 0.001. To examine the regulatory relationship between DLEU2 and E2F1, we modulated DLEU2 expression in HeLa and SiHa cells. DLEU2 knockdown reduced E2F1 protein levels (Fig. 4D), while its overexpression increased them (Fig. 4E). Conversely, E2F1 overexpression elevated DLEU2 RNA expression (Fig. 4F,G), indicating transcriptional activation of DLEU2 by E2F1. ChIP‑seq data demonstrated strong E2F1 occupancy at the DLEU2 promoter in HeLa cells (Fig. 4H). RNA pull‑down assays further confirmed direct binding of E2F1 protein to DLEU2 transcripts (Fig. 4I). Dual‑luciferase reporter assays revealed that DLEU2 enhances E2F1‑mediated transcriptional activation of its own promoter (Fig. 4J). This effect was abolished when E2F binding sites were mutated (Fig. 4K). Together, these findings are consistent with a model in which E2F1 transcriptionally activates DLEU2, while DLEU2 is associated with increased E2F1 protein abundance and may regulate E2F1 at post-transcriptional/post-translational levels. Direct mechanistic evidence for this regulatory association requires further investigation. Given that DLEU2 is associated with enhanced migration, invasion, and motility in cervical cancer cells, we next investigated whether these effects are mediated through E2F1. Rescue experiments were performed in HeLa cells by co‑knocking down DLEU2 while overexpressing E2F1. As shown in Fig. 5A–C, E2F1 overexpression partially restored the migratory, invasive, and motility capacities impaired by DLEU2 silencing. These results indicate that DLEU2 promotes malignant phenotypes in cervical cancer cells, at least in part, via its association with E2F1.Fig. 5Functional rescue assays. The HeLa cells were transfected with siRNAs for 24 h and the pCDNA-3.1 plasmids were then added. Transwell assay (A,B) and cell motility assay (C) were performed as previously described. (A) The migration ability of HeLa cells with DLEU2 knockdown and E2F1 overexpression. (B) The invasion ability of HeLa cells with DLEU2 knockdown and E2F1 overexpression. (C) The motility of HeLa cells with DLEU2 knockdown and E2F1 overexpression. Error bars represent the SD of the mean. **p < 0.01, ***p < 0.001. Scale bar: 500 µm. Functional rescue assays. The HeLa cells were transfected with siRNAs for 24 h and the pCDNA-3.1 plasmids were then added. Transwell assay (A,B) and cell motility assay (C) were performed as previously described. (A) The migration ability of HeLa cells with DLEU2 knockdown and E2F1 overexpression. (B) The invasion ability of HeLa cells with DLEU2 knockdown and E2F1 overexpression. (C) The motility of HeLa cells with DLEU2 knockdown and E2F1 overexpression. Error bars represent the SD of the mean. **p < 0.01, ***p < 0.001. Scale bar: 500 µm. DLEU2 modulates the expression of downstream target genes To investigate the functional role of the DLEU2–E2F1–mRNA axis in cervical cancer migration and invasion, we performed RNA‑seq following DLEU2 knockdown in SiHa cells. This yielded 1772 differentially expressed genes (DEGs) (|FC|> 2), comprising 736 upregulated and 1036 downregulated genes (Fig. 6A). The data are publicly accessible in the NCBI GEO database (accession GSE291247). Metascape‑based functional enrichment analysis linked these DEGs to processes including cell cycle regulation, cell motility, and cell adhesion (Fig. 6B). Network analysis further highlighted interconnected genes involved in motility and adhesion (Fig. 6C), with MMP9 and SNAI2 identified as key regulators. MMP9 promotes invasion through extracellular matrix degradation18, while SNAI2 drives epithelial–mesenchymal transition19. Together, these results suggest that DLEU2 contributes to cervical cancer progression by regulating genes implicated in cell adhesion and motility.Fig. 6Functional analysis of DLEU2 after knockdown in CC cell. (A) Volcano plot of differential gene expression analysis in SiHa cells. Differential analysis was performed using R and the screening criterion for DEGs was |FC|> 2. (B,C) Functional analysis of the 1772 DEGs identified after siDLEU2 was performed by R and Metascape for Biological Process (BP) and network construction. Functional analysis of DLEU2 after knockdown in CC cell. (A) Volcano plot of differential gene expression analysis in SiHa cells. Differential analysis was performed using R and the screening criterion for DEGs was |FC|> 2. (B,C) Functional analysis of the 1772 DEGs identified after siDLEU2 was performed by R and Metascape for Biological Process (BP) and network construction. To confirm the RNA‑seq findings and the regulatory function of DLEU2, mRNA and protein levels of SNAI2 and MMP9 were examined by qRT‑PCR and Western blotting, respectively. DLEU2 knockdown significantly reduced both mRNA and protein expression of SNAI2 and MMP9 in cervical cancer cells, consistent with the transcriptomic data (Fig. 7A,B). Gain‑of‑function experiments further demonstrated that overexpression of either DLEU2 or E2F1 upregulated SNAI2 and MMP9 at the mRNA level (Fig. 7C,D).Fig. 7DLEU2 modulates downstream molecules. (A,B) The expression of downstream target genes linked to cell adhesion and motility in CC cells with DLEU2 knockdown. After HeLa and SiHa cells transfected with siRNAs, the mRNA expression of genes was verified by qRT-PCR (A) and the protein expression was assessed by Western blot (B). (C) The mRNA expression level of genes in HeLa cells with DLEU2 overexpression was verified by qRT-PCR. (D) The mRNA expression level of genes in HeLa cells with E2F1 overexpression was verified by qRT-PCR. Error bars represent the SD of the mean. *p < 0.05, **p < 0.01, ***p < 0.001. (E) Working model of DLEU2 in CSCC. DLEU2 and E2F1 form a regulatory axis that correlates with altered expression of downstream target genes involved in cell migration and invasion in CSCC. DLEU2 modulates downstream molecules. (A,B) The expression of downstream target genes linked to cell adhesion and motility in CC cells with DLEU2 knockdown. After HeLa and SiHa cells transfected with siRNAs, the mRNA expression of genes was verified by qRT-PCR (A) and the protein expression was assessed by Western blot (B). (C) The mRNA expression level of genes in HeLa cells with DLEU2 overexpression was verified by qRT-PCR. (D) The mRNA expression level of genes in HeLa cells with E2F1 overexpression was verified by qRT-PCR. Error bars represent the SD of the mean. *p < 0.05, **p < 0.01, ***p < 0.001. (E) Working model of DLEU2 in CSCC. DLEU2 and E2F1 form a regulatory axis that correlates with altered expression of downstream target genes involved in cell migration and invasion in CSCC. Collectively, RNA‑seq profiling, functional enrichment analysis, and experimental validation indicate that DLEU2 promotes cervical cancer cell migration and invasion in vitro via its interaction with E2F1. This regulatory axis modulates the transcription of key effector genes such as SNAI2 and MMP9, which are involved in cell adhesion and motility (Fig. 7E). These results provide insight into a potential mechanism by which DLEU2 may contribute to CSCC cell migration and invasion and nominate the DLEU2–E2F1 axis as a potential therapeutic target for suppressing migration and invasion. Discussion CSCC pathogenesis involves complex genetic and epigenetic alterations, with persistent HR‑HPV infection being the primary etiological driver20,21. Despite advances in early detection, advanced CSCC remains a major clinical challenge due to limited therapeutic efficacy and significant toxicity of current regimens22. Thus, identifying the molecular drivers of migration and invasion is critical for improving patient outcomes. LncRNAs are key regulators of tumor progression5,6. Our previous work showed that DLEU2 promotes cervical cancer proliferation via cell‑cycle and NOTCH signaling13. Here, we extend these findings by demonstrating that DLEU2 is not only overexpressed in invasive CSCC and correlated with poor prognosis in advanced disease, but also functions as a potential driver of migration, invasion, and motility—key features of cancer cell motility and invasion. Mechanistically, we identified a regulatory association between DLEU2 and the transcription factor E2F1. While E2F1 is known to regulate cell proliferation and invasion17,23, our data reveal that it directly activates DLEU2 transcription, and in turn, DLEU2 binds to and may regulate E2F1 protein at the post‑transcriptional level, creating a potential positive feedback association. Through this interplay, DLEU2 and E2F1 may jointly influence transcriptional programs associated with invasive phenotypes. However, direct mechanistic evidence for how this regulatory association operates at the molecular level requires further investigation. Notably, we identified SNAI2 and MMP9 as critical downstream effectors of this axis. Our RNA‑seq and validation experiments demonstrated that DLEU2 knockdown significantly reduces both SNAI2 and MMP9 expression, while overexpression of either DLEU2 or E2F1 upregulates them. While the precise mechanism by which E2F1 regulates SNAI2 and MMP9 transcription remains to be fully defined, Functionally, SNAI2 is a master EMT regulator that enhances cell motility and suppresses epithelial adhesion19,24, whereas MMP9 degrades extracellular matrix components to facilitate invasion18,25. Thus, through the DLEU2/E2F1 axis, CSCC cells may simultaneously activate EMT‑driven motility and matrix remodeling programs, thereby coordinately promoting migratory and invasive capabilities in vitro. Our study therefore repositions DLEU2 from a linear pathway component to a central hub within a dynamic regulatory network that sustains CSCC aggressiveness. The DLEU2/E2F1 interaction offers a coherent explanation for the persistent activation of programs that promote migration and invasion and aligns with the poorer prognosis observed in patients with high co‑expression of both molecules. We acknowledge that the current conclusions are primarily based on in vitro models. Moreover, the proposed mechanism by which DLEU2 may stabilize E2F1 protein awaits further validation, and direct evidence for E2F1 binding to the promoters of SNAI2 and MMP9 has not yet been established. Future studies using additional cell lines, patient‑derived samples, and in vivo metastasis models, together with mechanistic investigations such as cycloheximide chase, proteasome inhibition, and chromatin immunoprecipitation assays, will be essential to fully validate the pathophysiological relevance and therapeutic potential of targeting the DLEU2/E2F1 axis in CSCC. Methods Preparation of clinical samples and RNA-sequencing analysis Seven CSCC samples and 7 normal cervical tissue samples were collected from the Gynecology Department of the First Affiliated Hospital of Chongqing Medical University in 2023. CC patients were pathologically diagnosed with invasive CSCC and their excised tumor samples were collected prior to undergoing chemotherapy, radiotherapy, or immunotherapy. Normal cervical tissues (controls) were obtained from women who had undergone hysterectomy and had no history of malignancy. The clinical pathological information of patients is shown in Supplementary Table S1. All samples were stored in RNAlater™ Stabilization Solution (ThermoFisher Scientific, USA) at − 80 °C according to the manufacturer’s protocol. RNA-sequencing was conducted by Knorigene Technologies (Chongqing, China) and the data analyzed with bioinformatics technology. This study was approved by the Ethics Committee, First Affiliated Hospital of Chongqing Medical University (No: 2023-78). Differential gene expression analysis RNA-Seq data underwent differential expression analysis using the edgeR package (Version 4.0.16) in R software. Chip data was analyzed for differential expression using the online tool GEO2R (https://www.ncbi.nlm.nih.gov/geo/geo2r/)26,27. Screening criteria for differentially expressed genes (DEGs) were set as |FC|> 2 and p-value < 0.05. Functional enrichment analysis and survival analysis Gene ontology (GO) analysis was conducted using PANTHER (https://pantherdb.org/) and the network constructed using Metascape (https://metascape.org/gp/index.html)28,29. The ggplot2 package (version 3.5.1) was used to draw diagrams for GO and KEGG analysis, with optimization of the interaction network performed using Cytoscape (version 3.6.0) software30. The relationship between DLEU2 expression and prognosis was analyzed by Kaplan–Meier curves using the survminer package (version 0.5.0) in R software. Cell culture The CC cell lines Hela and SiHa were obtained from the cell bank of the Chinese Academy of Sciences (Shanghai, China) and verified by Short Tandem Repeat (STR) profiling. Cells were cultured in high glucose DMEM medium (Hyclone, South Logan, UT, USA) supplemented with 10% fetal bovine serum (FBS) (Excell, Suzhou, China), 50 units/mL penicillin, and 50 mg/mL streptomycin. All cells were grown in a humidified incubator at 37 °C with an atmosphere of 5% CO2 and in a mycoplasma-free environment (Mycoplasma Removal Agent, Beyotime, Shanghai, China). Cell transfection The short interfering RNA (siRNA) targeting DLEU2 and negative control siRNA were synthesized by GenePharma (Shanghai, China), with the sequences listed in Supplementary Table S2. The empty vector (pCDH and pcDNA3.1) and overexpression vector (pCDH-DLEU2 and pcDNA3.1-E2F1) were purchased from Sangon Biotech (Shanghai, China). Cells were transfected with the corresponding plasmids or siRNAs using Lipofectamine RNAiMAX Transfection Reagent (Invitrogen, Carlsbad, CA, USA). All procedures were performed according to the manufacturer’s instructions. Cell wound healing and transwell assays Would healing and transwell assays were taken for the abilities of migration and invasion of CC cell. For would healing assay, transfected cells were cultured in 6 well plates to 100% confluence and a scratch was performed on monolayer cells. The images were photographed at 0 h and 24 h and the migration rate was quantified by the ImageJ (Version 1.48, https://imagej.net/ij/). For transwell migration assay, 100 μl serum-starved cells were seeded in the upper part of transwell chamber and 600 μl complete medium containing 10% FBS was added to the bottom chamber. After incubation for 24 h, the chamber was washed with PBS, fixed with 4% paraformaldehyde and stained with 0.1% crystal violet. Then the cells on the lower surface were counted and photographed in five random fields under an inverted fluorescence microscope. Transwell invasion assay were conducted similarly using the chamber coated with Matrigel. Cell motility assay Transfected cells were seeded into 6-well plates at approximately 20–30% confluence. A JULI Stage Real-time Cell History Recorder (NanoEntek, Seoul, South Korea) was then used to monitor cell motility, with images recorded every 15 min for 12 h. Cell motility was quantified by JULI STAT. Cellular RNA preparation and RNA-sequencing analysis After transfecting SiHa cells with the siRNAs, total cellular RNA was extracted using RNA TRIzol Reagent (Invitrogen, USA) and stored at − 80 °C. The RNA quality met the control standards. RNA sequencing analysis was performed by Knorigene Technologies (Chongqing, China) and the data was analyzed with bioinformatics technology. Quantitative real-time polymerase chain reaction (qRT-PCR) Total RNA from CC cells was isolated using Total RNA Kit I (Omega Bio-Tek, Norcross, GA, USA). cDNA synthesis was then performed with random primers and PrimeScript (TAKARA, Tokyo, Japan). RT-PCR was performed using TB Green® Premix Ex Taq™ II FAST qPCR (TAKARA, Tokyo, Japan). All procedures were carried out according to the manufacturer’s instructions, with GAPDH serving as an internal control. The primer sequences are listed in Supplementary Table S3. RNA pulldown assay Procedures for the cell RNA-pulldown experiment and the reagents used were the same as described previously31. Briefly, biotin-labeled RNA was transcribed in vitro and the RNA purified according to the manufacturer’s instructions. The cell lysate and beads were prepared according to methods described in the literature. The cell lysate preparation and beads were mixed and centrifuged, then placed on a magnetic rack to collect the supernatant. RNase inhibitor and biotin were added to the collected supernatant for RNA–protein incubation. The prepared beads were then added and co-incubated for RNA pulldown and finally washed with elution buffer. PBS and SDS loading buffer were then added and heated at 100 oC for 5–10 min before protein separation for Western blotting. Western blotting Western blotting was performed as described previously13. Briefly, cultured cells were lysed with RIPA lysis buffer supplemented with a protease inhibitor cocktail (Bimake, Houston, TX, USA). Protein concentrations were evaluated with the Quick Start™ Bradford kit (BioRad Laboratories, Hercules, CA, USA) and the standard Western blotting procedure was then performed. The antibody information used for Western blotting is listed in Supplementary Table S4. Dual-luciferase reporter assay In brief, the promoter region of DLEU2 was cloned into plasmid pGL4.10 to generate reporters. Three tandem consensus E2F binding sites were cloned into pGL4.27 to generate pGL4.27-3×E2F, and the mutation vector pGL4.27-3×E2Fm was constructed32. The plasmid pGL4.10, pGL4.27 and pGL4.27-3×E2F were constructed and preserved in our laboratory32. HeLa cells were then seeded into 24-well plates at approximately 60–70% confluence and co-transfected with the corresponding plasmids. After 48 h, the Dual-Luciferase Reporter Assay System (Promega, USA) was used to detect luciferase activity as described previously32. Statistical analysis Graphpad Prism 9.0 software was used to perform statistical analysis. All data were expressed as the mean ± SD and analyzed by Student’s t-test. p-values < 0.05 were considered to represent statistical significance. Supplementary Information Supplementary Information 1. Supplementary Information 2. Supplementary Information 3. Supplementary Information 4. Supplementary Information 5. Supplementary Information 6. Supplementary Information 7. Supplementary Information 8. Supplementary Information 1. Supplementary Information 2. Supplementary Information 3. Supplementary Information 4. Supplementary Information 5. Supplementary Information 6. Supplementary Information 7. Supplementary Information 8.